Schroder Investment Management Group Grows Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Schroder Investment Management Group grew its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 548.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 533,111 shares of the company’s stock after acquiring an additional 450,924 shares during the period. Schroder Investment Management Group owned about 0.93% of Olema Pharmaceuticals worth $2,991,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Intech Investment Management LLC purchased a new position in Olema Pharmaceuticals in the third quarter valued at about $163,000. Charles Schwab Investment Management Inc. lifted its position in Olema Pharmaceuticals by 168.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company’s stock worth $3,949,000 after acquiring an additional 207,565 shares in the last quarter. State Street Corp boosted its holdings in Olema Pharmaceuticals by 1.1% in the 3rd quarter. State Street Corp now owns 1,969,963 shares of the company’s stock worth $23,521,000 after acquiring an additional 21,986 shares during the period. Wellington Management Group LLP grew its position in Olema Pharmaceuticals by 10.8% in the third quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock valued at $11,972,000 after acquiring an additional 97,428 shares in the last quarter. Finally, EP Wealth Advisors LLC raised its stake in shares of Olema Pharmaceuticals by 5.2% during the third quarter. EP Wealth Advisors LLC now owns 48,655 shares of the company’s stock valued at $581,000 after purchasing an additional 2,407 shares during the period. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. decreased their target price on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Friday, March 28th. Oppenheimer restated an “outperform” rating and set a $25.00 target price (down from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th.

Insider Buying and Selling

In other Olema Pharmaceuticals news, major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of Olema Pharmaceuticals stock in a transaction dated Wednesday, January 8th. The shares were bought at an average cost of $5.76 per share, for a total transaction of $1,728,000.00. Following the transaction, the insider now owns 7,800,000 shares in the company, valued at $44,928,000. This represents a 4.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 19.40% of the stock is currently owned by company insiders.

Olema Pharmaceuticals Trading Down 3.0 %

Shares of NASDAQ:OLMA opened at $3.25 on Friday. Olema Pharmaceuticals, Inc. has a 12-month low of $3.15 and a 12-month high of $16.62. The firm has a market cap of $222.08 million, a PE ratio of -1.48 and a beta of 2.10. The company has a fifty day simple moving average of $4.75 and a 200 day simple moving average of $7.74.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.12. As a group, equities research analysts forecast that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.